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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT)
with myeloablative conditioning has previously been used
as a treatment for patients who suffer from hematological
malignancies. However, this approach involves considerable
toxicity, particularly in elderly patients and those exhibiting
severe organ dysfunctions. Therefore, reduced intensity con-
ditioning was designed, in order to more safely conduct HSCT
on such patients.
The allografts perform two important functions. The first
of these functions is the restoration of conditioning-induced
cytopenia, and the second is the exertion of an anti-tumor
effect, commonly referred to as the graft-versus-malignancy
effect (1, 2). A conditioning regimen is known to facilitate
the success of HSCT, but this does not appear to be crucial.
In some situations, the ability of HSCT to cure the patient
seems to be dependent to a greater degree on the immuno-
logical control of the malignancy by the graft (2). Several
investigators have reported comparable results for reduced
intensity and myeloablative transplantations in the treatment
of patients suffering from hematological malignancies of
diverse disease status (3-8). Reduced intensity conditioning
depends on graft-versus-tumor (GVT) effects for the eradi-
cation of malignant cells. When the intensity of condition-
ing is reduced, a loss of control of the malignant cells might
become apparent in the early period after transplantation. If
this is, indeed, the case, reduced intensity transplantation
may be difficult to perform on patients with advanced hema-
tological malignancies. Therefore, we have conducted a direct
comparison of the outcomes of reduced intensity and mye-
loablative transplantation in the treatment of patients exhibit-
ing advanced hematological malignancies.
MATERIALS AND METHODS
Patients
We compared the outcomes of allogeneic HSCT using
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Allogeneic Stem Cell Transplantation for Patients with Advanced
Hematological Malignancies: Comparison of Fludarabine-based Reduced
Intensity Conditioning versus Myeloablative Conditioning
We compared the outcomes of allogeneic hematopoietic stem cell transplantation
using reduced intensity and myeloablative conditioning for the treatment of patients
with advanced hematological malignancies. A total of 75 adult patients received
transplants from human leukocyte antigen-matched donors, coupled with either
reduced intensity (n=40; fludarabine/melphalan, 28; fludarabine/cyclophosphamide,
12) or myeloablative conditioning (n=35, busufan/cyclophosphamide). The patients
receiving reduced intensity conditioning were elderly, or exhibited contraindications
for myeloablative conditioning. Neutrophil and platelet engraftment occurred more
rapidly in the reduced intensity group (median, 9 days vs. 18 days in the myeloab-
lative group, p<0.0001; median 12 days vs. 22 days in the myeloablative group,
p=0.0001, respectively). Acute graft-versus-host disease (≥ ≥grade II) occurred at
comparable frequencies in both groups, while the incidence of hepatic veno-occlu-
sive disease was lower in the reduced intensity group (3% vs. 20% in the myeloab-
lative group, p=0.02). The overall 1-yr survival rates of the reduced intensity and
myeloablative group patients were 44% and 15%, respectively (p=0.16). The results
of present study indicate that patients with advanced hematological malignancies,
even the elderly and those with major organ dysfunctions, might benefit from reduced
intensity transplantation.
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reduced intensity or myeloablative conditioning for the treat-
ment of patients with advanced hematological malignancies.
Between January 2001 and December 2004, 75 adult patients,
all of whom exhibited advanced hematological malignan-
cies, received transplantations from human leukocyte anti-
gen (HLA)-matched donors, either related or unrelated, cou-
pled with myeloablative (n=40) or reduced intensity (n=35)
conditioning, at the Seoul National University Hospital in
Korea. Advanced hematological malignancies were defined
as follows: acute leukemia beyond 1st remission, chronic mye-
loid leukemia (CML) beyond 1st chronic phase (CP), refrac-
tory Non-Hodgkin’s lymphoma (NHL), and refractory mul-
tiple myeloma (MM) that had progressed after autologous
HSCT. A full explanation of the transplantation methods was
provided to the patients, and informed consent was obtained
from all patients who enrolled in the study. 
All patients receiving transplantation with reduced inten-
sity conditioning were determined to exhibit contraindica-
tions to the myeloablative approach. Contraindications to
myeloablative conditioning included advanced age, prior
HSCT, major organ dysfunction, or an ECOG performance
status of ≥3. The individual reasons for performing reduced
intensity HSCT are described in Table 1. 
Conditioning regimens
In the reduced intensity group, we used two different fluda-
rabine-based conditioning regimens (Table 2). Among these,
the melphalan-containing regimen was used for myeloid ma-
lignancies such as acute myeloid leukemia (AML) and CML,
and MM. The cyclophosphamide-containing regimen was
used for the treatment of lymphoid malignancies (acute lym-
phoblastic leukemia, NHL) except MM. However, the mel-
phalan-containing regimen was also applied to patients with
poor cardiac ejection fractions. Busulfan and cyclophosphamide
were used for all of the patients in the myeloablative group. 
GVHD prophylaxis and treatment
All patients in the reduced intensity group received cyclos-
porine (CSP) as a post-transplantation immunosuppressant.
CSP was scheduled to be administered at a dosage of 3 mg/
kg/day intravenously, or 6 mg/kg/day orally, from days -1 to
+30, and then tapered off until day +70 unless the patient
developed GVHD. All of the patients in the myeloablative
group received four doses of intravenous methotrexate (MTX)
combined with CSP (9). The intravenous CSP was replaced
by an oral dose in cases in which the patient could tolerate
it. The CSP was tapered off and discontinued 6 months after
HSCT, contingent on the absence of GVHD. The dosage of
CSP was determined on the basis of blood levels in both gro-
ups. Acute GVHD was graded from 0 to IV according to the
criteria established by Thomas (10), and chronic GVHD was
defined and classified according to the Sullivan’s criteria (11).
In both groups of patients, GVHD treatment normally con-
sisted of methylprednisolone and resumption of CSP, if already
tapered. 
Supportive care
Supportive cares between the groups were comparable. Pro-
phylaxis against infections was accomplished by the oral ad-
ministration of ciprofloxacin and fluconazole during the neu-
tropenic period, when the patient’s absolute neutrophil count
(ANC) was less than 1×109/L. Sulfamethoxazole/trimetho-
prim was administered as a prophylactic agent against Pneu-
mocystis jiroveci, after the ANC had risen to a level in excess of
1×109/L. Patients exhibiting chronic GVHD were treated
via prolonged sulfamethoxazole/trimethoprim prophylaxis. 
Statistical analyses
Means were compared by Student’s t-tests. Categorical
variables were compared by chi-squared tests. Overall sur-
vival and progression-free survival curves were determined
using Kaplan-Meier product-limit estimates. Survival curves
were compared by log-rank tests, taking the censored data
into account. The probability of nonrelapse mortality was
calculated using cumulative incidence estimates. Relapse was
considered to be a competing risk for nonrelapse mortality.
We used the Cox regression model to evaluate the indepen-
dent effects on survival of several variables. These variables
included: type of conditioning, gender of the patient and
ECOG PS, Eastern Cooperative Oncology Group Performance Status.
Reason No. of patients (%)
Older than 50 yr 24 (60%)
Poor performance (ECOG PS ≥3) 5 (12%)
Prior ablative transplant 6 (15%)
Cardiac dysfunction 3 (7%)
Recent fungal infection 3 (7%)
Renal failure 1 (3%)
Table 1. Reasons to perform reduced intensity transplantation
Conditioning regimen
No. of 
patients (%)
Reduced Intensity  40
Fludarabine (30 mg/m
2×5d)+Melphan (90 mg/m
2×2d) 24 (60)
Fludarabine (30 mg/m
2×5d)+Melphan (70 mg/m
2×2d) 4 (10)
Fludarabine (30 mg/m
2×5d)+Cyclophosphamide 12  (30)
(60 mg/kg×2d) 
Myeloablative 35
i.v. Busulfan (3.2 mg/kg×4d)+Cyclophosphamide 32 (91)
(60 mg/kg×2d)
oral Busulfan (4 mg/kg×4d)+Cyclophosphamide 3 (9)
(60 mg/kg×2d)
Table 2. Conditioning regimens used in hematopoietic stem cell
transplantation
i.v., intravenous.donor, patient age, type of hematological malignancy, stem
cell source, donor source, prior HSCT, and interval between
diagnosis and transplantation. All p-values were predicated
on likelihood ratio statistics, and were two-sided. Multivari-
ate p-values for a variable reflected the adjustments for all of
the other variables in the model. Statistical analyses were
conducted using the SPSS version 12.0 program (SPSS, Inc.,
Chicago, IL, U.S.A.).
RESULTS
Patient and transplant characteristics
The median follow-up times of the patients with reduced
intensity and myeloablative conditionings were 27 and 23
months, respectively. The characteristics of all patients are
summarized in Table 3. The median ages of the reduced in-
tensity and myeloablative groups were 50 yr (range, 21-70)
and 29 yr (range, 17-49) yr, respectively (p=0.0001). The
median ages of the donors for the reduced intensity and mye-
loablative groups were 46 and 31 yr (p=0.0001). The diag-
noses differed slightly between the two groups (p=0.014), as
there were more patients with NHL and MM in the reduced
intensity group, and also less patients with ALL. The medi-
an intervals between the diagnosis and transplantation of the
reduced intensity and myeloablative groups were 359 (range,
75-4,328) and 349 (range, 83-4,605) days (p=0.64). Ninety
percent of the patients in the reduced intensity group received
peripheral blood stem cells (PBSC), as compared with 17%
of the myeloablative group patients (p=0.0001). Sixty-eight
percent of the reduced intensity group patients and 66% of
the myeloablative group patients received transplants from
related matched donors (p=0.87). Six of the reduced intensi-
ty group patients (15%) had previously received autologous
HSCT, and all of them had gone into relapse before being
treated via reduced intensity transplantation, whereas none
of the myeloablative patients had ever received autologous
transplantation (p=0.03). The median cell dose infused for
the reduced intensity and myeloablative groups were 5.2×
106 CD34
+ cells/kg (range, 1.4-25.7×106 CD34
+ cells/kg),
and 3.3×106 CD34
+ cells/ kg (range, 0.9-13.1×106 CD34
+
cells/kg), respectively (p=0.003). The median duration of
hospital stay for the reduced intensity group patients was 30
days, which was significantly shorter than the 43 days for the
myeloablative group patients (p=0.01). 
Hematological recovery
Engraftment failure was detected in 1 patient in the reduced
intensity group and 4 patients in the myeloablative group.
This was not a significant difference (1/40 vs. 4/35, p=0.18).
Neutrophil engraftment (i.e., time to ANC>0.5×109/L)
occurred more rapidly in the reduced intensity group (medi-
an, 9 days; range, 0-19 days) than in the myeloablative group
(median, 18 days; range, 11-38 days) (p<0.0001). The time
required to achieve a platelet count in excess of 20×109/L
was 12 days (median; range, 7-28 days) in the reduced inten-
sity group, as compared with 22 days (median; range, 9-64
days) in the myeloablative group (p=0.0001). 
Graft-versus-host disease
The incidences of grades II to IV acute graft-versus-host
disease (GVHD) between the reduced intensity and myeloab-
lative groups were comparable, at 25% vs. 26%, respectively
(p=0.60). The median day of onset of acute GVHD in the
reduced intensity group was day +20 (range 11-35), and
also day +20 (range 13-59) in the myeloablative group (p=
0.46). The incidence of chronic GVHD among the patients
who survived more than 100 days after transplantation was
29% in the reduced intensity group and 14% in the myelo-
ablative group (p=0.30). 
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Characteristics
Reduced
Intensity
Myeloablative
p-
value
No. of patients 40 35
Median age (range), yr 50 (21-70) 29 (17-49) 0.0001
Donor age (range), yr 46 (20-66) 31 (17-63) 0.0001
Sex of patients
Male/Female 29/11 18/17 0.06
Sex of donors
Male/Female 29/11 24/11 0.71
Diagnosis, No. 0.014
AML 19 13
ALL 4 16
ABL 3 1
NHL 7 3
CML 4 2
MM 3 0
Time to transplantation,  359 (75-4328) 349 (83-4605) 0.64
days (range)
Stem cell source, No. (%) 0.0001
PBSC 36 (90) 6 (17)
BM 4 (10) 29 (83)
Type of transplant, No. (%) 0.87
MRD 27 (68) 23 (66)
URD 13 (32) 12 (34)
GVHD prophylaxis, No. (%)
Cyclosporine 40
Cyclosporine/MTX 35
Prior autologous transplant,  6 (15) 0 (0) 0.03
No. (%)
CD34+ cell dose (×10
6/kg) 5.2 (1.4-25.7) 3.3 (0.9-13.1) 0.003
Table 3. Patient characteristics
AML, acute myelogenous leukemia; ALL, acute lymphocytic leukemia;
ABL, acute biphenotypic leukemia; NHL, non-Hodgkin lymphoma; CML,
chronic myelogenous leukemia; MM, multiple myeloma; GVHD, graft-
versus-host disease; PBSC, peripheral blood stem cell; BM, bone mar-
row; MRD, matched related donor; URD, unrelated donor.230 I. Kim, K.-H. Lee, Y. Choi, et al.
Early toxicities
Hepatic veno-occlusive disease (VOD) developed in 1 of
the patients (3%) in the reduced intensity group, and 7 pati-
ents (20%) in the myeloablative group. These incidences were
statistically significant (p=0.02). Febrile neutropenia devel-
oped in 33 of the patients (83%) in the reduced intensity
group, whereas all of the myeloablative group patients exhib-
ited febrile neutropenia (p=0.01). We noted a trend toward
a higher incidence of bacteremia in the myeloablative group
(12 patients, 34%), as compared with the reduced intensity
group (8 patients, 20%, p=0.16). The frequencies of fungal
infection and cytomegalovirus (CMV) disease were similar
between the reduced intensity (7% and 3%) and myeloabla-
tive groups (9% and 3%). Toxicity profiles are summarized
in Table 4. 
Nonrelapse mortality
Nonrelapse death and disease recurrence were considered
to be competing events for the purposes of this analysis. We
detected no difference in the nonrelapse mortality (NRM) of
patients receiving reduced intensity and myeloablative con-
ditioning. Day-100 and 1-yr NRMs were 33% and 47% for
the reduced intensity group patients, as compared with 38%
and 56% in the myeloablative patients, respectively (p=0.68,
Fig. 1). The causes of NRM did not differ between the groups
(Table 5). The most frequently encountered cause of NRM
was infection in both the reduced intensity and myeloablative
groups (15% and 17%), followed by pulmonary complica-
tions and GVHD. Hepatic VOD, as a cause of NRM, was
more prevalent in the myeloablative group patients than in
the reduced intensity group patients (5% and 0%, p=0.10). 
Overall survival and progression-free survival
One year overall survival (OS) rates for the reduced inten-
Reduced 
Intensity (%)
Myeloablative
(%)
p-value
Acute GVHD (≥II) 10 (25) 7 (26) 0.60
Chronic GVHD 8 (29*) 3 (14*) 0.30
Hepatic VOD 1 (3) 7 (20) 0.02
Febrile neutropenia 33 (83) 35 (100) 0.013
Bacteremia 8 (20) 12 (34) 0.16
Fungal infection 3 (7) 3 (9) 1.0
CMV disease 1 (3) 1 (3) 1.0
Table 4. Toxicity and complication profile of the patients
GVHD, graft-versus-host disease; VOD, veno-occlusive disease; CMV,
cytomegalovirus
*Among the patients who survived more than 100 days.
Reduce intensity
(n=40)
Myeloablative
(n=35)
Causes of death, No. (%)
Infection 6 (15) 6 (17)
Pulmonary complication 5 (13) 3 (9)
GVHD 2 (5) 1 (3)
CNS 3 (8) 1 (3)
VOD of liver 0 (0) 2 (5)
CHF 1 (3) 0 (0)
HUS 0 (0) 1 (3)
ARF 1 (3) 0 (0)
Total 18 (45) 14 (40)
Cumulative incidence, % (p=0.68) 47 56
Table 5. Comparison of the causes of 1-yr nonrelapse mortality
for patients receiving either reduced intensity or myeloablative
transplants
GVHD, graft-versus-host-disease; CNS, central nervous system toxici-
ty; VOD, veno-occlusive disease; CHF, congestive heart failure; HUS,
hemolytic uremic syndrome; ARF, acute renal failure.
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Fig. 1. Cumulative incidences of nonrelapse mortality of patents
with advanced hematological malignancies treated by reduced
intensity and myeloablative conditionings. 
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Fig. 2. Overall survivals for patients with advanced hematological
malignancies after reduced intensity and myeloablative transplan-
tations.Allogeneic HSCT for Advanced Hematological Malignancies 231
sity and myeloablative groups were 44% and 15%, and the
2-yr rates were 36% and 12%, respectively (p=0.16, Fig. 2).
Univariate analysis was conducted using the following fac-
tors: conditioning regimen (reduced intensity versus myelo-
ablative), age, stem cell source (PBSC versus bone marrow),
donor type (related versus unrelated), prior autologous stem
cell transplantation, sex of donor, the interval from diagnosis
to transplantation, and diagnosis (acute leukemia and CML
versus NHL and MM). None of these factors were found to
significantly influence OS. In our multivariate analysis, using
Cox regression hazard models, age was determined to be the
single significant factor for OS (p=0.01; HR, 1.045; range,
1.011-1.081). We noted a clear trend toward more favorable
OS in the reduced intensity group patients. The adjusted
hazard ratio of the myeloablative group, as compared to that
of the reduced intensity group, with regard to OS, was 2.21
(p=0.09; range, 0.87-5.61). Conditioning type, donor type,
and interval from diagnosis to transplantation and disease
type were associated with p values of less than 0.1 (Table 6).
The proportional hazard assumption was satisfied for all vari-
ables in the model. Overall 1-yr progression-free survival
(PFS) rates of the reduced intensity and myeloablative group
patients were 30% and 10%, respectively (p=0.15, Fig. 3).
None of the factors utilized in the univariate and multivari-
ate analyses had any significant influence on PFS.
DISCUSSION
In this study, we compared the outcome of 40 reduced
intensity transplantations with 35 myeloablative transplan-
tations, all of which were conducted at a single institution
during the same span of time. Several differences were found
between 2 groups. Reduced intensity patients were older
and had more major organ dysfunctions than myeloablative
patients at the time of transplantation. Allogeneic stem cell
transplantation has the potential to cure some of patients with
advanced hematological malignancies, but some of the pati-
ents, specifically the elderly and those exhibiting severe organ
dysfunctions, could not be treated by myeloablative trans-
plantation. Reduced intensity conditioning was developed
in order to enable such patients to receive transplants (12-
14). Some physicians have raised concerns regarding the pos-
sibility of rapid disease progression and resultant treatment
failure after reduced intensity transplantation, particularly
in patients with advanced hematological malignancies. How-
ever, recent reports (3-8) comparing the outcomes of reduced
intensity and myeloablative transplantations have obtained
results which generally favor reduced intensity transplanta-
tion. Our data also support this conclusion. In this study,
the 1-yr OS of the reduced intensity and myeloablative groups
were 44% and 15%, respectively. Although this is not statis-
tically significant (p=0.16), we noted a clear trend toward
higher survival rates for the reduced intensity group. This
becomes even more impressive when considering that the
patients with reduced intensity conditioning were older, and
more frequently exhibited organ dysfunctions, than did the
patients with myeloablative conditioning at the time of trans-
plantation.
In this study, we employed two types of fludarabine-based
conditioning regimens. One involved melphalan, 180 mg/m2,
and the other included cyclophosphamide, 120 mg/kg. The
dosages of these drugs (melphalan and cyclophosphamide)
were relatively higher than have been used in other fludara-
bine-based conditioning regimens which included melpha-
lan or cyclophosphamide (8, 15-17). Therefore, the potent
anti-malignancy effect associated with the relatively intense
reduced intensity conditioning employed in this study might
explain the similarities between the PFS rates of the reduced
intensity and myeloablative groups in the short-term, and
may have also facilitated the establishment of the graft-ver-
sus-malignancy effect. Clinical results using identical dosages
of melphalan (15) or cyclophosphamide (18) for good-risk
patients resulted in PFS rates of 57% and 75%, respectively. 
Factor Hazard ratio 95% CI p-value
Conditioning, myeloablative 2.20 0.87-5.61 0.09
Stem cell source, PBSC 0.56 0.24-1.31 0.18
Donor type, URD 2.00 0.93-4.30 0.07
Patient age, older*  1.05 1.01-1.08 0.01
Donor sex, female 1.23 0.63-2.42 0.55
Interval from Dx to TPL, >1 yr 0.56 0.30-1.07 0.08
Disease type
� , non-leukemia 2.33 0.86-6.31 0.09
Table 6. Multivariate proportional hazard analysis on overall sur-
vival
CI, confidence interval; PBSC, peripheral blood stem cell; URD, unre-
lated donor; Dx, diagnosis; TPL, transplantation. *Older, the hazard ratio
of older person is 1.05 by annual increase; 
�
Disease type, advanced
leukemia versus all others.
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Fig. 3. Progression free survivals for patients with advanced hema-
tological malignancies after reduced intensity and myeloablative
transplantations. Hematological recovery after reduced intensity transplan-
tation has generally been reported to occur fairly rapidly.
According to our results, the median days required for the
completion of neutrophil and platelet engraftment were 9
and 12 days, and the engraftment rates were significantly
more rapid than those associated with myeloablative trans-
plantation. Such rapid engraftments were reproducibly re-
ported in early studies regarding reduced intensity transplan-
tation (12, 13). In our study, the engraftment failure rate in
the reduced intensity group was quite low, comparable to that
of the myeloablative group (1/40 vs. 4/35, p=0.18). Reduced
intensity conditioning has been known to be associated with
a higher risk of engraftment failure than myeloablative con-
ditioning (19). However, the incidence of engraftment fail-
ure appears to differ with different reduced intensity condi-
tioning regimens. For example, the administration of fluda-
rabine, combined with 2 Gy of TBI, resulted in a 12% rejec-
tion frequency (19). The combination of fludarabine com-
bined with melphalan (8), or the combination of fludarabine
with cyclophosphamide (18), as in our study, have tended to
report relatively low graft rejection rates.
The development and severity of GVHD has been correlat-
ed with cytotoxic tissue injury and the resultant inflamma-
tory cytokine milieu (20). Some investigators have reported
lower acute GVHD incidence rates in cases of reduced inten-
sity transplantation (21), while contradictory results also exist
(3, 5, 6). The diversity of conditioning regimens, stem cell
sources, and GVHD prophylaxis protocols in reduced inten-
sity transplantation might be one reason for this discrepan-
cy. In this study, the incidence of acute GVHD (≥Gr II) in
the reduced intensity group (25%) was fairly similar to that
of the myeloablative group (26%). The onset of acute GVHD
was reported to have been delayed in cases of reduced intensity
transplantation, but we noted no differences in acute GVHD
onset between our study groups. The single use of CSP as a
GVHD prophylaxis and a rapid tapering off of the treatment
might explain why we observed no such differences. We also
noted a trend toward a higher incidence of chronic GVHD
in the reduced intensity transplantation patients (29% vs.
14%). Extant reports also differ (5, 22) with regard to the inci-
dence rates of chronic GVHD in reduced intensity transplan-
tation patients. We believed that higher proportions of PBSC
(90% of reduced intensity transplantation) might have ex-
plained the higher incidence of chronic GVHD noted in the
reduced intensity transplantation group (23).
Most reports, although some exceptions exist, have asso-
ciated reduced intensity transplantation with less severe infec-
tious complications, especially with regard to bacterial infec-
tions (24-27), than are seen in myeloablative transplantation.
The lower incidence of infectious complications in reduced
intensity transplantation has been explained as follows: i)
myeloablative conditioning, which causes an extensive break-
down of mucosal barriers, might result in bacterial translo-
cations within immunocompromised hosts (24, 28), ii) the
shorter neutropenic period and prolonged persistence of host
immunity after reduced intensity transplantation might also
contribute to a lower risk of infection (29). Our study revealed
similar results. The incidence of febrile neutropenia (83%)
was determined to be significantly lower in the reduced inten-
sity transplantation patients, as compared with the ablative
transplantation group (100%). We noted a trend toward a
lower incidence of bacteremia in the reduced intensity trans-
plantation group (25%), as compared to the myeloablative
transplantation group (43%). However, the degree to which
infection contributed to NRM appeared to be similar between
the groups (15% and 17%). It is possible that the poor per-
formance status and frequent active infections at the time of
transplantation among the patients with reduced intensity
conditioning explain, at least in part, the similar infectious
death rate between the groups in our study.
The incidence of hepatic VOD in the reduced intensity
group was lower than those detected in the myeloablative
group, and this difference was significant in our study (3%
vs. 20%). In other studies (5, 30), similar results have been
reported. Myeloablative conditioning has been associated
with harmful cytotoxicity, and appears to result in an inflam-
matory cytokine milieu around the hepatocytes (31, 32).
GVHD prophylaxis containing methotrexate, which was
used only in the myeloablative transplantation group in this
study, might also have contributed to the higher incidence
rates of VOD in the myeloablative group (33).
The cumulative NRM of the reduced intensity and mye-
loablative transplantation groups were reported to be signif-
icantly lower in the reduced intensity group (32% vs. 50%
(3) and 16% vs. 30% [5]). However, some investigators have
reported similar cumulative NRM incidence rates (4, 6). We
detected no differences in the NRM incidence rates between
the groups in this study (47% vs. 56%), although our study
involved a somewhat higher incidence rate than was report-
ed in previous studies. However, it should be kept in mind
that all of the patients in this study had been heavily treat-
ed, and were suffering from advanced disease at the time of
transplantation. The reduced intensity group patients were
all individuals at high risk for NRM (due to old age, poor
performance, prior transplantation, recent fungal infections,
or major organ dysfunction).
This study clearly has some unique merits. The outcomes
of reduced intensity and myeloablative transplantation were
determined for the patients treated at a single institution
during the same period. Therefore, the so-called ‘center effect’
and ‘time effect’, which tend to confound the results of ret-
rospective multicenter or registry studies, had no influence
on our results. Also, in our study, the conditioning regimens
of the reduced intensity and myeloablative transplantation
groups could be assured to be relatively homogeneous.
In conclusion, the results of the current study indicate that
patients who suffer from advanced hematological malignan-
cies, even the elderly and those with major organ dysfunc-
232 I. Kim, K.-H. Lee, Y. Choi, et al.tions, might benefit from reduced intensity transplantation.
However, this study has several limitations. Firstly, it was a
retrospective study. Secondly, the sample size was fairly small.
Thirdly, this study did not select for a specific disease type.
Therefore, in order to refine applications of allogeneic stem
cell transplantation, a large scale randomized clinical trial of
reduced intensity and myeloablative conditioning will be re-
quired. 
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